ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
How Do ED Drugs Compare? Cialis vs Viagra vs Levitra vs Stendra
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 274359" data-attributes="member: 3"><p><h3><a href="https://www.semanticscholar.org/paper/Predictors-of-Phosphodiesterase-Type-5-Inhibitor-in-Albarakati-El-Tholoth/cdf0d2563409734e706ee395ba6057ab694a9e34" target="_blank">Predictors of Phosphodiesterase Type 5 Inhibitor Treatment Failure in Patients Diagnosed With Erectile Dysfunction</a></h3><p></p><p>Introduction: Erectile dysfunction (ED) is a prevalent condition, especially in aging populations, with significant implications for quality of life. While phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line treatment, a substantial percentage of patients do not respond satisfactorily. This study aimed to identify predictors of PDE5I treatment failure in ED patients.</p><p></p><p> Methods: Data from January 2016 to January 2022 was reviewed for patients with ED who either failed PDE5I treatment or had a successful outcome. Demographic, medical, and laboratory data were collected and analyzed. Patients with contraindications or who did not complete the treatment were excluded.</p><p></p><p>Results: The treatment failure group comprised 288 patients, while 225 age-matched patients formed the control responder group. There were no significant differences in marriage duration, comorbidities, smoking, or BMI. However, HbA1c levels, free testosterone, and SHBG were significantly different between the two groups. Conclusion: This study found that <strong>high HbA1c levels, low free testosterone, and high sex hormone-binding globulin (SHBG) </strong>were associated with PDE5I treatment failure. Managing high HbA1c levels and addressing hormonal imbalances may enhance PDE5I treatment effectiveness in ED patients. However, further research is needed to explore other factors contributing to treatment outcomes.</p><p></p><p>[URL unfurl="true"]https://www.discountedlabs.com/blog/predictors-of-ed-drug-treatment-failure-in-patients-diagnosed-with-erectile-dysfunction[/URL]</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 274359, member: 3"] [HEADING=2][URL='https://www.semanticscholar.org/paper/Predictors-of-Phosphodiesterase-Type-5-Inhibitor-in-Albarakati-El-Tholoth/cdf0d2563409734e706ee395ba6057ab694a9e34']Predictors of Phosphodiesterase Type 5 Inhibitor Treatment Failure in Patients Diagnosed With Erectile Dysfunction[/URL][/HEADING] Introduction: Erectile dysfunction (ED) is a prevalent condition, especially in aging populations, with significant implications for quality of life. While phosphodiesterase type 5 inhibitors (PDE5Is) are the first-line treatment, a substantial percentage of patients do not respond satisfactorily. This study aimed to identify predictors of PDE5I treatment failure in ED patients. Methods: Data from January 2016 to January 2022 was reviewed for patients with ED who either failed PDE5I treatment or had a successful outcome. Demographic, medical, and laboratory data were collected and analyzed. Patients with contraindications or who did not complete the treatment were excluded. Results: The treatment failure group comprised 288 patients, while 225 age-matched patients formed the control responder group. There were no significant differences in marriage duration, comorbidities, smoking, or BMI. However, HbA1c levels, free testosterone, and SHBG were significantly different between the two groups. Conclusion: This study found that [B]high HbA1c levels, low free testosterone, and high sex hormone-binding globulin (SHBG) [/B]were associated with PDE5I treatment failure. Managing high HbA1c levels and addressing hormonal imbalances may enhance PDE5I treatment effectiveness in ED patients. However, further research is needed to explore other factors contributing to treatment outcomes. [URL unfurl="true"]https://www.discountedlabs.com/blog/predictors-of-ed-drug-treatment-failure-in-patients-diagnosed-with-erectile-dysfunction[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
When Testosterone Is Not Enough
How Do ED Drugs Compare? Cialis vs Viagra vs Levitra vs Stendra
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top